NearWave Optical Molecular Monitoring

Korábbi kezelés

• Prior breast cancer requiring surgery or radiation in either breast

Más betegség

• Inflammatory breast cancer

Egyéb

• Patients with significant bruising or hematoma from diagnostic breast biopsy, as determined by clinical judgement (mild ecchymosis okay)
• Pregnant or nursing due to changes in breast architecture
• Patients with a BMI of ≥ 40, unless the lesion is near the surface (<3 cm from the skin surface), based on diagnostic scan measurements
• Patients with any tattoos on their breasts

• Women ≥ 18 years old at the time of informed consent
• Ability to provide written informed consent and HIPAA authorization
• Patients who:
  • have been diagnosed with invasive breast cancer by tissue biopsy and have not yet started any therapy for the disease; a) Subtype HER2 positive (IHC 3+ or if IHC 2+, then positive by FISH), with any ER status, OR b) Subtype TNBC, defined by: HER2 negative and ER/PR negative or low (ER and PR ≤ 9%, weak staining)
  • with ≥2 cm tumor size in the largest dimension as measured by ultrasound, MRI, or mammography. If multifocal disease, at least one tumor must measure ≥2 cm
  • are planned to receive neoadjuvant chemotherapy followed by surgery
  • Will be at least two weeks out from biopsy of the primary lesion at the time of baseline visit
  • Have a palpable breast mass as determined by a treating physician